

REVIEW

Neuroactive steroids, their metabolites, and neuroinflammation

Silvia Giatti^{1,2*}, Mariaserena Boraso^{1*}, Roberto Cosimo Melcangi^{1,2} and Barbara Viviani¹

¹Dipartimento di Scienze Farmacologiche e Biomolecolari and ²Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy

(Correspondence should be addressed to R C Melcangi who is now at Dipartimento di Scienze Farmacologiche e Biomolecolari, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy; Email: roberto.melcangi@unimi.it)

*(S Giatti and M Boraso contributed equally to this work)

Abstract

Neuroinflammation represents a common feature of many neurodegenerative diseases implicated both in their onset and progression. Neuroactive steroids act as physiological regulators and protective agents in the nervous system. Therefore, the attention of biomedical research has been recently addressed in evaluating whether neuroactive steroids, such as progestagens, androgens, and estrogens may also affect neuroinflammatory pathways. Observations so far obtained suggest a general anti-inflammatory effect with a beneficial relapse on several neurodegenerative experimental models, thus confirming the potentiality of a neuroprotective strategy based on neuroactive steroids. In this scenario, neuroactive steroid metabolism and the sophisticated machinery involved in their signaling are becoming especially attractive. In particular, because metabolism of neuroactive steroids as well as expression of their receptors is affected during the course of neurodegenerative events, a crucial role of progesterone and testosterone metabolites in modulating neuroinflammation and neurodegeneration may be proposed. In the present review, we will address this issue, providing evidence supporting the hypothesis that the efficacy of neuroactive steroids could be improved through the use of their metabolites.

Journal of Molecular Endocrinology (2012) **49**, R125–R134

Introduction

Neuroactive steroids act as important physiological regulators of CNS functions (Melcangi *et al.* 2008, 2011, Panzica *et al.* 2012). Moreover, as demonstrated in experimental models of several neurodegenerative disorders, the administration of neuroactive steroids is able to favor several protective/repairative processes like inhibition of neuronal death, promotion of neurogenesis, and myelination, as well as reduction of neuroinflammation (Brinton & Wang 2006, Garcia-Segura & Balthazart 2009, Melcangi & Garcia-Segura 2010, Melcangi *et al.* 2011, Kipp *et al.* 2012, Panzica *et al.* 2012, Schumacher *et al.* 2012). Intriguing is the modulation of this last process. Neuroinflammation is shared by a number of pathologies, ranging from neurodegenerative to psychiatric diseases (Glass *et al.* 2010, Tansey 2010, Tansey & Goldberg 2010, Wee Yong 2010, Wuwongse *et al.* 2010, Meyer *et al.* 2011) and represents an early response to any perturbation of the CNS physiology leading to dysfunction and degeneration when deregulated

(Block *et al.* 2007). Thus, the possibility to modulate this phenomenon becomes valuable in terms of preventing disease progression.

An emerging issue in the field of neuroactive steroids is the role of progesterone (PROG) and testosterone metabolites. In particular, the observation that metabolites are i) more active than the precursor molecule (Melcangi *et al.* 2008), ii) appear to be necessary for some of the effects exerted by PROG or testosterone (Ghoumari *et al.* 2003, Giachino *et al.* 2003, 2004, Ciriza *et al.* 2004, 2006, Djebaili *et al.* 2004, He *et al.* 2004, Pesaresi *et al.* 2010a, Sun *et al.* 2012), and iii) their synthesis is impaired in CNS diseases (Labombarda *et al.* 2006, Meffre *et al.* 2007, Caruso *et al.* 2008, 2010, Giatti *et al.* 2010, Naylor *et al.* 2010, Pesaresi *et al.* 2010b, Melcangi *et al.* 2012) suggest that these molecules might share a higher therapeutic impact than classical hormones like PROG and testosterone.

The present review will recapitulate what is known about the anti-inflammatory properties of neuroactive steroids, with a particular focus on PROG and testosterone metabolites.

Neuroactive steroids: state of the art

The nervous system is a well-known target for the endocrine effects of hormonal steroids coming from peripheral steroidogenic glands. However, the nervous system is also controlled in a paracrine and autocrine manner by steroids directly synthesized by neurons and glial cells, named neurosteroids (Baulieu 1998). More recently, this concept was expanded into the neuroactive steroid family, including hormonal steroids, neurosteroids, and synthetic steroids that are able to regulate several neuronal functions (Melcangi *et al.* 2008).

Synthesis and metabolism of neuroactive steroids occur in neurons and glial cells (Garcia-Segura & Melcangi 2006, Melcangi *et al.* 2008, Panzica & Melcangi 2008, Pelletier 2010). Steroidogenesis is a process highly compartmentalized in a sequence of reactions, which implies as a first step the translocation of cholesterol from the cytoplasm to the mitochondrial membrane (Fig. 1). This is a limiting step hormonally controlled and mediated by the StAR (Lavaque *et al.* 2006*a,b*) and 18 kDa translocator protein (Papadopoulos *et al.* 2006). In the mitochondria, the enzyme P450 side chain cleavage (P450scc) converts cholesterol into pregnenolone (PREG), which is further transformed into PROG or DHEA in the endoplasmic reticulum (Melcangi *et al.* 2008). Notably, these

molecules exert effects on the CNS *per se*, but may undergo metabolic transformations leading to the formation of neuroactive metabolites. Due to their lipophilic structure, neuroactive steroids move from one cell to another. This greatly impacts their metabolism that will be ruled by the enzymatic repertoire expressed in different cell types. For example, DHEA can be converted into androstenediol, and subsequently into testosterone, or into androstenedione in all the cells of the CNS (Melcangi *et al.* 2008). In neurons, androstenedione, as well as testosterone, may be converted by the enzyme P450 aromatase (ARO) to estrone and 17 β -estradiol (17 β -E₂) respectively. This occurs also in astrocytes, which display ARO, but not in microglia (Garcia-Segura *et al.* 2003). In neurons, as well as in astrocytes, PROG and testosterone may be metabolized by the enzymatic complex formed by 5 α -reductase (5 α -R) and 3 α -hydroxysteroid dehydrogenase (3 α -HSD) into dihydroprogesterone (DHP) and tetrahydroprogesterone (THP), also known as allopregnanolone, or dihydrotestosterone (DHT) and 5 α -androstane-3 α ,17 β -diol (3 α -Diol) respectively (Melcangi *et al.* 2008). Although these pathways are shared by microglia, this cell type is not able to produce PREG or PROG. Moreover, expressing 17 β -HSD, they synthesize androstenediol from DHEA (Jellinck *et al.* 2007) and testosterone from




Figure 1 Schematic representation of neurosteroidogenesis. Arrows represent cellular localization in neurons (red), astrocytes (green), and microglia (blue).

androstenedione (Jellinck *et al.* 2006, 2007). Finally, since ARO is not expressed, microglial cells produce estradiol only from estrone and not from testosterone (Gottfried-Blackmore *et al.* 2008).

The metabolism of PROG and testosterone has a deep impact on the mechanism of action of these neuroactive steroids. Indeed, while DHP, like PROG, is able to interact with the classical steroid receptor, the PROG receptor (PR; Melcangi *et al.* 2008), THP is a potent ligand of a non-classical steroid receptor, such as the GABA-A receptor (Lambert *et al.* 2003, Belelli & Lambert 2005). Similarly, DHT is able to interact with the androgen receptor (AR) while 3α -diol is a ligand of the GABA-A receptor (Melcangi *et al.* 2008). Thus, metabolic conversion of PROG and testosterone into their derivatives might differently and specifically modulate the mechanism of action of the respective precursor molecules by recruiting CNS-specific pathways.

Both neurons and glial cells express classical steroid receptors (Melcangi *et al.* 2001, 2008, Brinton *et al.* 2008). However, not all glial cell types express the same repertoire of steroid receptors and their expression changes in relation to the activation state of cells, to the regional localization and the developmental stage. For instance, estrogen receptor α (ER α) is expressed in microglial cells, while ER β , AR, and PR seem not to be under physiological conditions (Sierra *et al.* 2007, 2008). In male rats, AR-positive astrocytes were observed in the cerebral cortex, but only in postnatal day 10 animals (DonCarlos *et al.* 2006), while in the adult animals AR-positive astrocytes were observed in the arcuate nucleus and in the hippocampal formation (Tabori *et al.* 2005, DonCarlos *et al.* 2006).

Both steroid receptor expression and metabolism are modified by different insults. In rats, for example, brain injury induces the expression of ER α in vimentin or glial fibrillary acidic protein (GFAP)-positive astrocytes and of AR in Griffonia simplicifolia lectin-I or MHC-II-positive microglia, suggesting that the expression of several receptors in different cell types is necessary for the correct modulation of the response to the insults (García-Ovejero *et al.* 2002).

Neuroinflammation: the main features

Neuroinflammation is a local CNS inflammatory reaction, which represents the coordinated cellular and molecular response to injurious stimuli, aimed at eliminating or neutralizing them and restoring tissue integrity (Fig. 2). The appropriate regulation of this process facilitates recovery, while uncontrolled neuroinflammation contributes to pathology.

Microglia and astrocytes are the two cell types resident within the CNS and mainly involved in the

local organization of the neuroinflammatory response. Microglia are involved in regulatory processes critical for development, maintenance of neuronal environment, repair, and injury. In the normal, healthy brain, these cells are in a so-called 'resting state' characterized by low expression of membrane receptors that serve immunological functions (Hanisch & Kettenmann 2007). Although 'resting', microglia constantly monitor for changes in the surrounding environment and are ready to get activated to fight off any threats to tissue integrity. When stimulated, microglia acquire an amoeboid morphology and present an upregulated catalog of surface molecules (Oehmichen & Gencic 1975, Cho *et al.* 2006), such as MHC, chemokine receptors, and CD14 (Rock *et al.* 2004). This activated state also coincides with the production of soluble mediators both detrimental, such as pro-inflammatory cytokines, reactive oxygen species, and reactive nitrogen species (Sawada *et al.* 1989, Moss & Bates 2001, Viviani *et al.* 2001, Liu *et al.* 2002, Tansey *et al.* 2007), and beneficial (i.e. anti-inflammatory cytokines and tropic factors) (Morgan *et al.* 2004, Liao *et al.* 2005, Muller *et al.* 2006; Fig. 2). A balanced production of those factors contributes to restore CNS function.

While microglial cells are generally considered as the main resident immune cells of the brain, it is important to note that astrocytes are immunocompetent cells as well, and they also act as important regulators of CNS inflammation. Astrocytes are the most abundant glial cells and are essential for brain homeostasis and neuronal functions (Benarroch 2005, Farina *et al.* 2007). Like microglia, astrocytes become activated – a process known 'astrogliosis', which is characterized by altered gene expression, increased expression of marker molecules (i.e. GFAP and vimentin), hypertrophy, and proliferation (Ridet *et al.* 1997). Activated astrocytes release as well a wide array of immune mediators such as cytokines, chemokines, and growth factors, contributing either to neuroprotective or neurotoxic effects (Farina *et al.* 2007) raised by microglia (Fig. 2).

The neuroinflammatory response is not only confined to glial cells. Peripheral immune cells also, and no less crucially, participate (Schwartz *et al.* 2006). In fact, the release of the above mediators by glial cells leads to the recruitment of macrophages, monocytes, and lymphocytes (T and B cells) that participate in sustaining the local response to an acute or chronic CNS insult (Schwartz *et al.* 2006). This easily occurs through the compromised blood–brain barrier (BBB), a feature accompanying several CNS diseases. T-cell invasion of the CNS determines the organization of an adaptive immune response whose quality will be defined by the characteristics of the invading lymphocytes. In fact, in response to inflammatory events, CD4+T helper (Th) cells can potentially differentiate




Figure 2 Inflammatory processes that occur in the CNS. Different events (inflammation, infection, aging, neurodegenerative diseases) could be the causative factor for the activation of microglia and astrocytes, the immune cells of CNS. It leads to a series of concomitant detrimental and beneficial effects. Harmful glial-mediated effects include the production of cytotoxic molecules (ROS, reactive oxygen species and RNS, reactive nitrogen species) and pro-inflammatory cytokines (IL1 β , TNF- α , IL6). By contrast, glial cells also mediate positive and reparative effects, including the release of trophic factors and anti-inflammatory cytokines (IL10, TGF- β), and the clearance of cellular debris by phagocytosis. The neuroinflammation is often accompanied by the presence of peripheral immune cells (macrophages and lymphocytes) that cross the compromised BBB and sustain the inflammatory reactions in the CNS.

into Th1, Th2, and Th17 subsets depending on the cytokine milieu (Liew 2002). Th1 cells are largely considered to be pro-inflammatory in nature, aiding in the activation of macrophages and other immune cell subsets (Wee Yong 2010), while Th2 cells are considered regulatory/anti-inflammatory by virtue of the cytokines produced, which include interleukin (IL)4, IL5, IL10, and IL13 (Wee Yong 2010). A third arm of differentiation of the Th cell is to the pro-inflammatory Th17 subset characterized by the production of IL17 (Kebir *et al.* 2007). Finally another subclass is regulatory T cells (Tregs), involved in the control of immune homeostasis and self-tolerance (Mills 2004).

As it appears from the mediators produced and the cell types recruited, neuroinflammation is a two-edged sword. In most cases it constitutes a beneficial process

for the CNS, since it tends to minimize the injury and contributes to the repair of damaged tissue (Czlonkowska & Kurkowska-Jastrzebska 2011). However, in some situations (Fig. 2), when the insults may persist and/or the inflammatory process may get out of control, the chronic activation of the immune response could be harmful. A shift from a homeostatic balance of inflammatory mediators toward a pro-inflammatory state has been observed not only in 'classical' pathological conditions but also in aging (Fig. 2; Viviani & Boraso 2011). In particular, the balance between pro- and anti-inflammatory cytokines is lost during aging, possibly contributing to an unsuccessful maintenance at the molecular, cellular, and tissue level leading to age-related dysfunction as well as to an enhanced brain vulnerability to diseases, pathogens, environmental factors, or stress.

Neuroactive steroids as neuroinflammatory modulators

It is well established that numerous pathologies show differences in etiology and progression according to sex. Autoimmune diseases, for example, and in particular, multiple sclerosis (MS), have a female preponderance (Hughes 2012). Also neurodegenerative diseases, like for instance Alzheimer's disease (AD) and Parkinson's disease (PD), show differences between the sexes in susceptibility and outcomes in response to therapies (Melcangi & Garcia-Segura 2010). Indeed, women seem to be more affected than men in AD and protected from PD, with a better response to levodopa treatment (Melcangi & Garcia-Segura 2010). Moreover, sex differences on response to treatment are also reported after brain injury, with women showing better cognitive performance than men after therapy (Melcangi & Garcia-Segura 2010).

The influence of the hormonal milieu on the etiopathogenesis of these conditions has been supported also by other observations done both in humans and animal models. Actually, changes in neuroactive steroid levels are evident in autopsy brain tissue from AD, PD, and MS patients (Naylor *et al.* 2010, Luchetti *et al.* 2011a,b, Noorbakhsh *et al.* 2011); similarly significant modifications happen also in the CNS of PD and experimental autoimmune encephalomyelitis (EAE) models as well as of brain or spinal trauma (Labombarda *et al.* 2006, Meffre *et al.* 2007, Caruso *et al.* 2010, Giatti *et al.* 2010, 2012, Melcangi *et al.* 2012). Moreover, the variation of hormonal levels in conditions such as castration, pregnancy, and the phase of estrous cycle may also influence the course of pathologies (Melcangi & Garcia-Segura 2010).

As mentioned above, neuroinflammation is an important feature of these pathologies. Therefore, also the effect of neuroactive steroids on neuro-inflammatory pathways has been specifically analyzed. Several observations have been obtained *in vitro*, using cultures of microglia or astrocytes exposed to lipopolysaccharide (LPS). These findings have been recently reviewed (Arevalo *et al.* 2012), therefore, in this study, we focus our attention on *in vivo* observations obtained in experimental animal models. In particular, several observations have been obtained in MS animal models and following CNS injury. For instance, in EAE animals, estrogen treatment reduces the pro-inflammatory cytokines, such as tumor necrosis factor (TNF)- α , interferon (IFN)- γ , and IL6; chemokines and their receptors (e.g. CCL2, CCL3, CXCL2, CCR2, CCR3, and CXCR5), and increases anti-inflammatory transforming growth factor (TGF)- β 2 and -3 (Spence & Voskuhl 2012). Moreover, their treatment suppresses Th1 (Bebo *et al.* 2001, Offner 2004) and Th17 cell (Wang *et al.* 2009) functions, promoting Treg cell

regulation (Offner 2004). In the same animal model, other evidences report that PROG was able to reduce inflammatory markers (i.e. microglia activation, IL1 β , IL2, and IL17) (Yates *et al.* 2010, Giatti *et al.* 2012).

In experimental models of injury, such as the traumatic brain injury (TBI) model, PROG treatment reduces edema, accumulation of astrocytes in the cortex, nuclear factor kappa B (NF κ B) p65, active C3 fragments, IL1 β , and TNF- α (Garcia-Estrada *et al.* 1993, Grossman *et al.* 2004, He *et al.* 2004, Pettus *et al.* 2005, Feeser & Loria 2011). Moreover, it attenuates the reaction of astrocytes and microglial/macrophage cells in spinal cord injury models (Garay *et al.* 2011, Labombarda *et al.* 2011) and decreases the lesion volume and the expression of IL1 β , inducible nitric oxide synthase (iNOS; Gibson *et al.* 2008), ionized calcium-binding adapter molecule 1 (Iba1), and cyclooxygenase-2 in ischemic stroke models (Jiang *et al.* 2011). Also, testosterone treatment in TBI decreases vimentin, MHCII, and GFAP immunoreactive cells (Garcia-Estrada *et al.* 1993, Barreto *et al.* 2007) and after middle cerebral artery occlusion decreases GFAP immunostaining and astrocyte hypertrophy around the infarcted area (Pan *et al.* 2005). All these data underline the ability of neuroactive steroids to positively influence the inflammatory events in different neurodegenerative conditions by suppressing the pro-inflammatory and emphasizing the anti-inflammatory response.

Anti-inflammatory effects have been also reported after treatment with testosterone or PROG metabolites. Again, in the EAE model DHT reduces pro-inflammatory IFN- γ whereas it increases anti-inflammatory IL10 (Dalal *et al.* 1997), and THP treatment reduces the immunoreactivity of Iba1, the monocytoïd cell marker, and CD3 ϵ , a lymphocytic marker, in lumbar spinal cord (Noorbakhsh *et al.* 2011). In particular, THP diminishes phorbol ester myristate-induced expression of pro-inflammatory genes in primary monocyte-derived macrophage cultures, while it does not affect antigen-specific proliferation of CD4+T cells as well as the expression of IFN- γ and IL17 *in vitro* in the presence of myelin oligodendrocyte glycoprotein (Noorbakhsh *et al.* 2011). These results, together with the absence of monocytoïd and lymphocytic markers in the spinal cord, suggest that THP specifically inhibits the activation of both macrophages and microglia as well as the penetration of circulating lymphocytes and macrophages toward the CNS, thus preventing the exacerbation of the immune response. Consistent with the role of a deregulated inflammatory response in the progression of CNS diseases, THP treatment diminishes EAE severity (Noorbakhsh *et al.* 2011). THP anti-inflammatory effect seems to apply also to CNS diseases different in nature from EAE. Indeed, in ischemic stroke, THP is able to reduce the infarct size,

production of pro-inflammatory cytokines like TNF- α and IL6, as well as to protect BBB disruption (Ishrat *et al.* 2010). Moreover, in the TBI model this neuroactive metabolite of PROG decreases the expression of IL1 β , TNF- α (He *et al.* 2004) and increases CD55, a potent inhibitor of the complement convertases that are activators of the inflammatory cascade (VanLandingham *et al.* 2007). Although no direct evidence exists, GABA-A receptors have been evoked to explain part of the anti-inflammatory effect of THP. Proofs of concept are the observations that i) THP *per se* does not act through the classical intra-nuclear PR but in its action recruits GABA-A receptors (Lambert *et al.* 2003, Beelli & Lambert 2005), ii) this neurotransmitter receptor is also expressed on resident and circulating monocytoid cells of the immune system (Alam *et al.* 2006, Bhat *et al.* 2010) as well as on astrocyte and microglia (Lee *et al.* 2011), and iii) GABA suppresses the reactive response of glia to the inflammatory stimulants LPS and IFN- γ by inhibiting induction of inflammatory pathways mediated by NF κ B and P38 MAP kinase (Lee *et al.* 2011). Nevertheless, as THP can be reversibly converted to DHP (Melcangi *et al.* 2008), the recruitment of the classical nuclear PR cannot be radically excluded.

As demonstrated by Barreto *et al.* (2007), the effect of testosterone in reducing reactive astroglia and microglia in the TBI model seems to be ascribed to the conversion of this neuroactive steroid into its metabolites, 17 β -E₂ (i.e. by ARO activity) or DHT (i.e. by the enzyme 5 α -R). Indeed, treatment with these metabolites may partially mimic the effect of testosterone (Barreto *et al.* 2007). Similar observations were obtained in the case of PROG. Indeed, after kainic acid injection, PROG as well as its metabolites (i.e. DHP and THP) reduces reactive gliosis (Ciriza *et al.* 2004). Inhibition of PROG-metabolizing enzymes (i.e. 5 α -R and 3 α -HSD) blocked the anti-gliotic effect of PROG (Ciriza *et al.* 2006). This is a very interesting finding in light of the observation that in experimental models reproducing different neurological diseases, the levels of neuroactive steroids and particularly the conversions of PROG and testosterone into their metabolites are affected (Labombarda *et al.* 2006, Meffre *et al.* 2007, Caruso *et al.* 2008, 2010, Giatti *et al.* 2010, Pesaresi *et al.* 2010b, Melcangi *et al.* 2012). On this basis, it is possible to hypothesize that treatment with metabolites might be more effective than treatment with the substrate molecule in regulating the neuroinflammatory response. Thus, exploring the potential anti-inflammatory effects of neuroactive steroid metabolites, together with their mechanism of action, in neurodegenerative events may provide important advances to a more effective therapeutic approach. This hypothesis is strengthened by recent *in vitro* observations, obtained with androstenediol (i.e. a metabolite of DHEA)

showing that i) LPS decreases the expression of 17 β -HSD (i.e. the enzyme converting DHEA into androstenediol) in microglia cultures and ii) androstenediol, through the interaction with ER β , represses the transcription of pro-inflammatory mediators such as IL6, IL1 β , and iNOS in microglia or astrocytes (Saijo *et al.* 2011). In line with these *in vitro* observations, *in vivo* treatment with androstenediol has been reported to be more potent than its precursor (i.e. DHEA) in blocking the ability of LPS to induce IL6 expression in the substantia nigra (Saijo *et al.* 2011).

Concluding remarks and perspectives

Neuroinflammation is a process that requires to be regulated because both deficient and excessive responses will result in pathological conditions. In particular, chronic inflammation is a long-standing and often self-perpetuating response that may negatively affect neuronal function and viability, thus contributing to disease progression. Understanding CNS immunity requires attention to the temporary relation between insult, inflammatory response, and control of pro- and anti-inflammatory processes. Like in a symphony, each of these aspects is necessary and instrumental for a harmonic composition that will be reached only under tight control of every single step. Based on the dual role of inflammation, a proper anti-inflammatory approach should not simply block the onset of the process. In doing so, the deleterious effects of inflammation will be inhibited, but at the same time the inflammatory pathways that lead to neuroprotection will not be preserved. A possible approach to control neuroinflammation could consist of the restoration of the feedback mechanisms that enable the brain to regulate




Figure 3 Progesterone and testosterone metabolites, reducing pro-inflammatory and promoting anti-inflammatory response of activated glial cells, may represent novel therapeutic approaches to reduce brain inflammation.

the process. This goal might be reached respecting the timing and local control of inflammation in order to boost the endogenous neuroprotective response directly or interfering with the mechanisms that blunt this response in conditions of injury. In this scenario, neuroactive steroids together with their metabolites provide several points for discussion and present several attractive features to be considered as effective and promising anti-inflammatory mediators. Neuroactive steroids have been proved to positively affect neuroinflammation, also by inhibiting the pro-inflammatory and reinforcing the anti-inflammatory response (Fig. 3). Their action is regulated by a dynamic system based on a differential expression and distribution of specific metabolic enzymes and receptors, both sensitive to pathological stages. In addition, neuroactive steroid metabolism, by providing a plethora of compounds characterized by different potency and mechanisms, might modulate diverse aspects of neuroinflammation. Although the observations so far obtained suggest a beneficial effect of neuroactive steroids, timing, location, metabolism, and molecular mechanisms recruited in modulating neuroinflammation remain to be still clarified. Deciphering the setting of the neuroactive steroid system along with the development of different stages of neuroinflammation and the cross-talk between these two processes will be instrumental for the development of novel approaches aimed at restoring a 'physiological' neuroinflammation.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding

The financial support of Fondazione San Paolo (Progetto Neuroscienze PF2009.1180) to R C M is gratefully acknowledged.

References

Alam S, Laughton DL, Walding A & Wolstenholme AJ 2006 Human peripheral blood mononuclear cells express GABAA receptor subunits. *Molecular Immunology* **43** 1432–1442. (doi:10.1016/j.molimm.2005.07.025)

Arevalo MA, Santos-Galindo M, Acaz-Fonseca E, Azcoitia I & Garcia-Segura LM 2012 Gonadal hormones and the control of reactive gliosis. *Hormones and Behavior*. In press. (doi:10.1016/j.yhbeh.2012.02.021)

Barreto G, Veiga S, Azcoitia I, Garcia-Segura LM & Garcia-Ovejero D 2007 Testosterone decreases reactive astroglia and reactive microglia after brain injury in male rats: role of its metabolites, oestradiol and dihydrotestosterone. *European Journal of Neuroscience* **25** 3039–3046. (doi:10.1111/j.1460-9568.2007.05563.x)

Baulieu EE 1998 Neurosteroids: a novel function of the brain. *Psychoneuroendocrinology* **23** 963–987.

Bebo BF Jr, Fyfe-Johnson A, Adlard K, Beam AG, Vandenbark AA & Offner H 2001 Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. *Journal of Immunology* **166** 2080–2089.

Belelli D & Lambert JJ 2005 Neurosteroids: endogenous regulators of the GABA(A) receptor. *Nature Reviews. Neuroscience* **6** 565–575. (doi:10.1038/nrn1703)

Benarroch EE 2005 Neuron–astrocyte interactions: partnership for normal function and disease in the central nervous system. *Mayo Clinic Proceedings* **80** 1326–1338. (doi:10.4065/80.10.1326)

Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW & Steinman L 2010 Inhibitory role for GABA in autoimmune inflammation. *PNAS* **107** 2580–2585. (doi:10.1073/pnas.0915139107)

Block ML, Zecca L & Hong JS 2007 Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nature Reviews. Neuroscience* **8** 57–69. (doi:10.1038/nrn2038)

Brinton RD & Wang JM 2006 Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. *Current Alzheimer Research* **3** 185–190. (doi:10.2174/156720506777632817)

Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ *et al.* 2008 Progesterone receptors: form and function in brain. *Frontiers in Neuroendocrinology* **29** 313–339. (doi:10.1016/j.yfrne.2008.02.001)

Caruso D, Scurati S, Maschi O, De Angelis L, Roglio I, Giatti S, Garcia-Segura LM & Melcangi RC 2008 Evaluation of neuroactive steroid levels by liquid chromatography–tandem mass spectrometry in central and peripheral nervous system: effect of diabetes. *Neurochemistry International* **52** 560–568. (doi:10.1016/j.neuint.2007.06.004)

Caruso D, D'Intino G, Giatti S, Maschi O, Pesaresi M, Calabrese D, Garcia-Segura LM, Calza L & Melcangi RC 2010 Sex-dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis. *Journal of Neurochemistry* **114** 921–932. (doi:10.1111/j.1471-4159.2010.06825.x)

Cho BP, Song DY, Sugama S, Shin DH, Shimizu Y, Kim SS, Kim YS & Joh TH 2006 Pathological dynamics of activated microglia following medial forebrain bundle transection. *Glia* **53** 92–102. (doi:10.1002/glia.20265)

Ciriza I, Azcoitia I & Garcia-Segura LM 2004 Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity *in vivo*. *Journal of Neuroendocrinology* **16** 58–63. (doi:10.1111/j.1365-2826.2004.01121.x)

Ciriza I, Carrero P, Frye CA & Garcia-Segura LM 2006 Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. *Journal of Neurobiology* **66** 916–928. (doi:10.1002/neu.20293)

Czlonkowska A & Kurkowska-Jastrzebska I 2011 Inflammation and gliosis in neurological diseases – clinical implications. *Journal of Neuroimmunology* **231** 78–85. (doi:10.1016/j.jneuroim.2010.09.020)

Dalal M, Kim S & Voskuhl RR 1997 Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. *Journal of Immunology* **159** 3–6.

Djebaili M, Hoffman SW & Stein DG 2004 Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. *Neuroscience* **123** 349–359. (doi:10.1016/j.neuroscience.2003.09.023)

DonCarlos LL, Sarkey S, Lorenz B, Azcoitia I, Garcia-Ovejero D, Huppenbauer C & Garcia-Segura LM 2006 Novel cellular phenotypes and subcellular sites for androgen action in the forebrain. *Neuroscience* **138** 801–807. (doi:10.1016/j.neuroscience.2005.06.020)

Farina C, Aloisi F & Mehl E 2007 Astrocytes are active players in cerebral innate immunity. *Trends in Immunology* **28** 138–145. (doi:10.1016/j.it.2007.01.005)

- Feeser VR & Loria RM 2011 Modulation of traumatic brain injury using progesterone and the role of glial cells on its neuroprotective actions. *Journal of Neuroimmunology* **237** 4–12. (doi:10.1016/j.jneuroim.2011.06.007)
- Garay L, Tungler V, Deniselle MC, Lima A, Roig P & De Nicola AF 2011 Progesterone attenuates demyelination and microglial reaction in the lysocleithin-injured spinal cord. *Neuroscience* **192** 588–597. (doi:10.1016/j.neuroscience.2011.06.065)
- García-Estrada J, Del Rio JA, Luquin S, Soriano E & García-Segura LM 1993 Gonadal hormones down-regulate reactive gliosis and astrocyte proliferation after a penetrating brain injury. *Brain Research* **628** 271–278. (doi:10.1016/0006-8993(93)90964-O)
- García-Ovejero D, Veiga S, García-Segura LM & Doncarlos LL 2002 Glial expression of estrogen and androgen receptors after rat brain injury. *Journal of Comparative Neurology* **450** 256–271. (doi:10.1002/cne.10325)
- García-Segura LM & Balthazart J 2009 Steroids and neuroprotection: new advances. *Frontiers in Neuroendocrinology* **30** v–ix. (doi:10.1016/j.yfrne.2009.04.006)
- García-Segura LM & Melcangi RC 2006 Steroids and glial cell function. *Glia* **54** 485–498. (doi:10.1002/glia.20404)
- García-Segura LM, Veiga S, Sierra A, Melcangi RC & Azcoitia I 2003 Aromatase: a neuroprotective enzyme. *Progress in Neurobiology* **71** 31–41. (doi:10.1016/j.pneurobio.2003.09.005)
- Ghoumari AM, Ibanez C, El-Etr M, Leclerc P, Eychenne B, O'Malley BW, Baulieu EE & Schumacher M 2003 Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. *Journal of Neurochemistry* **86** 848–859. (doi:10.1046/j.1471-4159.2003.01881.x)
- Giachino C, Galbiati M, Fasolo A, Peretto P & Melcangi RC 2003 Neurogenesis in the subependymal layer of the adult rat: a role for neuroactive derivatives of progesterone. *Annals of the New York Academy of Sciences* **1007** 335–339. (doi:10.1196/annals.1286.032)
- Giachino C, Galbiati M, Fasolo A, Peretto P & Melcangi RC 2004 Effects of progesterone derivatives, dihydroprogesterone and tetrahydroprogesterone, on the subependymal layer of the adult rat. *Journal of Neurobiology* **58** 493–502. (doi:10.1002/neu.10290)
- Giatti S, D'Intino G, Maschi O, Pesaresi M, García-Segura LM, Calza L, Caruso D & Melcangi RC 2010 Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. *Neurochemistry International* **56** 118–127. (doi:10.1016/j.neuint.2009.09.009)
- Giatti S, Caruso D, Boraso M, Abbiati F, Ballarini E, Calabrese D, Pesaresi M, Rigolio R, Santos-Galindo M, Viviani B *et al.* 2012 Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. *Journal of Neuroendocrinology* **24** 851–861. (doi:10.1111/j.1365-2826.2012.02284.x)
- Gibson CL, Gray LJ, Bath PM & Murphy SP 2008 Progesterone for the treatment of experimental brain injury: a systematic review. *Brain* **131** 318–328. (doi:10.1093/brain/awm183)
- Glass CK, Saijo K, Winner B, Marchetto MC & Gage FH 2010 Mechanisms underlying inflammation in neurodegeneration. *Cell* **140** 918–934. (doi:10.1016/j.cell.2010.02.016)
- Gottfried-Blackmore A, Sierra A, Jellinck PH, McEwen BS & Bulloch K 2008 Brain microglia express steroid-converting enzymes in the mouse. *Journal of Steroid Biochemistry and Molecular Biology* **109** 96–107. (doi:10.1016/j.jsbmb.2007.12.013)
- Grossman KJ, Goss CW & Stein DG 2004 Effects of progesterone on the inflammatory response to brain injury in the rat. *Brain Research* **1008** 29–39. (doi:10.1016/j.brainres.2004.02.022)
- Hanisch UK & Kettenmann H 2007 Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nature Neuroscience* **10** 1387–1394. (doi:10.1038/nrn1997)
- He J, Evans CO, Hoffman SW, Oyesiku NM & Stein DG 2004 Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Experimental Neurology* **189** 404–412. (doi:10.1016/j.expneurol.2004.06.008)
- Hughes GC 2012 Progesterone and autoimmune disease. *Autoimmunity Reviews* **11** A502–A514. (doi:10.1016/j.autrev.2011.12.003)
- Ishrat T, Sayeed I, Atif F, Hua F & Stein DGCP 2010 Progesterone and allopregnanolone attenuate blood–brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. *Experimental Neurology* **226** 183–190. (doi:10.1016/j.expneurol.2010.08.023)
- Jellinck PH, Kaufmann M, Gottfried-Blackmore A, Croft G, Byford V, McEwen BS, Jones G & Bulloch K 2006 Dehydroepiandrosterone (DHEA) metabolism in the brain: identification by liquid chromatography/mass spectrometry of the delta-4-isomer of DHEA and related steroids formed from androstenedione by mouse BV2 microglia. *Journal of Steroid Biochemistry and Molecular Biology* **98** 41–47. (doi:10.1016/j.jsbmb.2005.07.006)
- Jellinck PH, Kaufmann M, Gottfried-Blackmore A, McEwen BS, Jones G & Bulloch K 2007 Selective conversion by microglia of dehydroepiandrosterone to 5-androstenediol-A steroid with inherent estrogenic properties. *Journal of Steroid Biochemistry and Molecular Biology* **107** 156–162. (doi:10.1016/j.jsbmb.2007.04.004)
- Jiang C, Cui K, Wang J & He Y 2011 Microglia and cyclooxygenase-2: possible therapeutic targets of progesterone for stroke. *International Immunopharmacology* **11** 1925–1931. (doi:10.1016/j.intimp.2011.08.001)
- Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B & Prat A 2007 Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. *Nature Medicine* **13** 1173–1175. (doi:10.1038/nm1651)
- Kipp M, Amor S, Krauth R & Beyer C 2012 Multiple sclerosis: neuroprotective alliance of estrogen–progesterone and gender. *Frontiers in Neuroendocrinology* **33** 1–16. (doi:10.1016/j.yfrne.2012.01.001)
- Labombarda F, Pianos A, Liere P, Eychenne B, Gonzalez S, Cambourg A, De Nicola AF, Schumacher M & Guennoun R 2006 Injury elicited increase in spinal cord neurosteroid content analyzed by gas chromatography mass spectrometry. *Endocrinology* **147** 1847–1859. (doi:10.1210/en.2005-0955)
- Labombarda F, Gonzalez S, Lima A, Roig P, Guennoun R, Schumacher M & De Nicola AF 2011 Progesterone attenuates astro- and microgliosis and enhances oligodendrocyte differentiation following spinal cord injury. *Experimental Neurology* **231** 135–146. (doi:10.1016/j.expneurol.2011.06.001)
- Lambert JJ, Bellelli D, Peden DR, Vardy AW & Peters JA 2003 Neurosteroid modulation of GABAA receptors. *Progress in Neurobiology* **71** 67–80. (doi:10.1016/j.pneurobio.2003.09.001)
- Lavaque E, Mayen A, Azcoitia I, Tena-Sempere M & García-Segura LM 2006a Sex differences, developmental changes, response to injury and cAMP regulation of the mRNA levels of steroidogenic acute regulatory protein, cytochrome p450_{scc}, and aromatase in the olivocerebellar system. *Journal of Neurobiology* **66** 308–318. (doi:10.1002/neu.20221)
- Lavaque E, Sierra A, Azcoitia I & García-Segura LM 2006b Steroidogenic acute regulatory protein in the brain. *Neuroscience* **138** 741–747. (doi:10.1016/j.neuroscience.2005.05.060)
- Lee M, Schwab C & McGeer PL 2011 Astrocytes are GABAergic cells that modulate microglial activity. *Glia* **59** 152–165. (doi:10.1002/glia.21087)
- Liao H, Bu WY, Wang TH, Ahmed S & Xiao ZC 2005 Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function. *Journal of Biological Chemistry* **280** 8316–8323. (doi:10.1074/jbc.M412730200)
- Liew FY 2002 T(H)1 and T(H)2 cells: a historical perspective. *Nature Reviews. Immunology* **2** 55–60. (doi:10.1038/nri705)
- Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL & Hong JS 2002 Role of nitric oxide in inflammation-mediated neurodegeneration. *Annals of the New York Academy of Sciences* **962** 318–331. (doi:10.1111/j.1749-6632.2002.tb04077.x)

- Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Morales RR, Frajese GV & Swaab DF 2011a Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. *Neurobiology of Aging* **32** 1964–1976. (doi:10.1016/j.neurobiolaging.2009.12.014)
- Luchetti S, Huitinga I & Swaab DF 2011b Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. *Neuroscience* **191** 6–21. (doi:10.1016/j.neuroscience.2011.04.010)
- Meffre D, Pianos A, Liere P, Eychenne B, Cambourg A, Schumacher M, Stein DG & Guennoun R 2007 Steroid profiling in brain and plasma of male and pseudopregnant female rats after traumatic brain injury: analysis by gas chromatography/mass spectrometry. *Endocrinology* **148** 2505–2517. (doi:10.1210/en.2006-1678)
- Melcangi RC & Garcia-Segura LM 2010 Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. *Hormones and Behavior* **57** 2–11. (doi:10.1016/j.yhbeh.2009.06.001)
- Melcangi RC, Magnaghi V, Galbiati M & Martini L 2001 Glial cells: a target for steroid hormones. *Progress in Brain Research* **132** 31–40. (doi:10.1016/S0079-6123(01)32063-0)
- Melcangi RC, Garcia-Segura LM & Mensah-Nyagan AG 2008 Neuroactive steroids: state of the art and new perspectives. *Cellular and Molecular Life Sciences* **65** 777–797. (doi:10.1007/s00018-007-7403-5)
- Melcangi RC, Panzica G & Garcia-Segura LM 2011 Neuroactive steroids: focus on human brain. *Neuroscience* **191** 1–5. (doi:10.1016/j.neuroscience.2011.06.024)
- Melcangi RC, Caruso D, Levandis G, Abbiati F, Armentero MT & Blandini F 2012 Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease. *Journal of Molecular Neuroscience* **46** 177–183. (doi:10.1007/s12031-011-9570-y)
- Meyer U, Schwarz MJ & Muller N 2011 Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. *Pharmacology and Therapeutics* **132** 96–110. (doi:10.1016/j.pharmthera.2011.06.003)
- Mills KH 2004 Regulatory T cells: friend or foe in immunity to infection? *Nature Reviews. Immunology* **4** 841–855. (doi:10.1038/nri1485)
- Morgan SC, Taylor DL & Pocock JM 2004 Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. *Journal of Neurochemistry* **90** 89–101. (doi:10.1111/j.1471-4159.2004.02461.x)
- Moss DW & Bates TE 2001 Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. *European Journal of Neuroscience* **13** 529–538. (doi:10.1046/j.1460-9568.2001.01418.x)
- Muller FJ, Snyder EY & Loring JF 2006 Gene therapy: can neural stem cells deliver? *Nature Reviews. Neuroscience* **7** 75–84. (doi:10.1038/nrn1829)
- Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, Strauss JL, Allen TB, Massing MW, Payne VM *et al.* 2010 Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. *Biochimica et Biophysica Acta* **1801** 951–959. (doi:10.1016/j.bbali.2010.05.006)
- Noorbakhsh F, Ellestad KK, Maingat F, Warren KG, Han MH, Steinman L, Baker GB & Power C 2011 Impaired neurosteroid synthesis in multiple sclerosis. *Brain* **134** 2703–2721. (doi:10.1093/brain/awr200)
- Oehmichen W & Gencic M 1975 Experimental studies on kinetics and functions of monuclear phagocytes of the central nervous system. *Acta Neuropathologica (Suppl 6)* 285–290.
- Offner H 2004 Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. *Journal of Neuroscience Research* **78** 603–624. (doi:10.1002/jnr.20330)
- Pan Y, Zhang H, Acharya AB, Patrick PH, Oliver D & Morley JE 2005 Effect of testosterone on functional recovery in a castrate male rat stroke model. *Brain Research* **1043** 195–204. (doi:10.1016/j.brainres.2005.02.078)
- Panzica GC & Melcangi RC 2008 The endocrine nervous system: source and target for neuroactive steroids. *Brain Research Reviews* **57** 271–276. (doi:10.1016/j.brainresrev.2008.02.002)
- Panzica GC, Balthazart J, Frye CA, Garcia-Segura LM, Herbison AE, Mensah-Nyagan AG, McCarthy MM & Melcangi RC 2012 Milestones on steroids and the nervous system: 10 years of basic and translational research. *Journal of Neuroendocrinology* **24** 1–15. (doi:10.1111/j.1365-2826.2011.02265.x)
- Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR *et al.* 2006 Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. *Trends in Pharmacological Sciences* **27** 402–409. (doi:10.1016/j.tips.2006.06.005)
- Pelletier G 2010 Steroidogenic enzymes in the brain: morphological aspects. *Progress in Brain Research* **181** 193–207. (doi:10.1016/S0079-6123(08)81011-4)
- Pesaresi M, Giatti S, Calabrese D, Maschi O, Caruso D & Melcangi RC 2010a Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats. *Journal of Molecular Neuroscience* **42** 135–139. (doi:10.1007/s12031-010-9344-y)
- Pesaresi M, Maschi O, Giatti S, Garcia-Segura LM, Caruso D & Melcangi RC 2010b Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. *Hormones and Behavior* **57** 46–55. (doi:10.1016/j.yhbeh.2009.04.008)
- Pettus EH, Wright DW, Stein DG & Hoffman SW 2005 Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Research* **1049** 112–119. (doi:10.1016/j.brainres.2005.05.004)
- Ridet JL, Malhotra SK, Privat A & Gage FH 1997 Reactive astrocytes: cellular and molecular cues to biological function. *Trends in Neuroscience* **20** 570–577. (doi:10.1016/S0166-2236(97)01139-9)
- Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR & Peterson PK 2004 Role of microglia in central nervous system infections. *Clinical Microbiology Reviews* **17** 942–964. (doi:10.1128/CMR.17.4.942-964.2004)
- Saijo K, Collier JG, Li AC, Katzenellenbogen JA & Glass CK 2011 An ADIOL-ER β -CtBP transrepression pathway negatively regulates microglia-mediated inflammation. *Cell* **145** 584–595. (doi:10.1016/j.cell.2011.03.050)
- Sawada M, Kondo N, Suzumura A & Marunouchi T 1989 Production of tumor necrosis factor- α by microglia and astrocytes in culture. *Brain Research* **491** 394–397. (doi:10.1016/0006-8993(89)90078-4)
- Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C & Ghoumari AM 2012 Progesterone synthesis in the nervous system: implications for myelination and myelin repair. *Frontiers in Neuroscience* **6** 10. (doi:10.3389/fnins.2012.00010)
- Schwartz M, Butovsky O, Bruck W & Hanisch UK 2006 Microglial phenotype: is the commitment reversible? *Trends in Neuroscience* **29** 68–74. (doi:10.1016/j.tins.2005.12.005)
- Sierra A, Gottfried-Blackmore AC, McEwen BS & Bulloch K 2007 Microglia derived from aging mice exhibit an altered inflammatory profile. *Glia* **55** 412–424. (doi:10.1002/glia.20468)
- Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS & Bulloch K 2008 Steroid hormone receptor expression and function in microglia. *Glia* **56** 659–674. (doi:10.1002/glia.20644)

- Spence RD & Voskuhl RR 2012 Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. *Frontiers in Neuroendocrinology* **33** 105–115. (doi:10.1016/j.yfrme.2011.12.001)
- Sun C, Ou X, Farley JM, Stockmeier C, Bigler S, Brinton RD & Wang JM 2012 Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. *Current Alzheimer Research* **9** 473–480.
- Tabori NE, Stewart LS, Znamensky V, Romeo RD, Alves SE, McEwen BS & Milner TA 2005 Ultrastructural evidence that androgen receptors are located at extranuclear sites in the rat hippocampal formation. *Neuroscience* **130** 151–163. (doi:10.1016/j.neuroscience.2004.08.048)
- Tansey MG 2010 Inflammation in neuropsychiatric disease. *Neurobiology of Disease* **37** 491–492. (doi:10.1016/j.nbd.2009.12.004)
- Tansey MG & Goldberg MS 2010 Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. *Neurobiology of Disease* **37** 510–518. (doi:10.1016/j.nbd.2009.11.004)
- Tansey MG, McCoy MK & Frank-Cannon TC 2007 Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. *Experimental Neurology* **208** 1–25. (doi:10.1016/j.expneurol.2007.07.004)
- VanLandingham JW, Cekic M, Cutler S, Hoffman SW & Stein DGCP 2007 Neurosteroids reduce inflammation after TBI through CD55 induction. *Neuroscience Letters* **425** 94–98. (doi:10.1016/j.neulet.2007.08.045)
- Viviani B & Boraso MS 2011 Cytokines and neuronal channels: a molecular basis for age-related decline of neuronal function? *Experimental Gerontology* **46** 199–206. (doi:10.1016/j.exger.2010.09.008)
- Viviani B, Corsini E, Binaglia M, Galli CL & Marinovich M 2001 Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 *in vitro*. *Neuroscience* **107** 51–58. (doi:10.1016/S0306-4522(01)00332-3)
- Wang C, Dehghani B, Li Y, Kaler LJ, Vandenbark AA & Offner H 2009 Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. *Immunology* **126** 329–335. (doi:10.1111/j.1365-2567.2008.03051.x)
- Wee Yong V 2010 Inflammation in neurological disorders: a help or a hindrance? *Neuroscientist* **16** 408–420. (doi:10.1177/1073858410371379)
- Wuwongse S, Chang RC & Law AC 2010 The putative neurodegenerative links between depression and Alzheimer's disease. *Progress in Neurobiology* **91** 362–375. (doi:10.1016/j.pneurobio.2010.04.005)
- Yates MA, Li Y, Chlebeck P, Proctor T, Vandenbark AA & Offner H 2010 Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis. *Journal of Neuroimmunology* **220** 136–139. (doi:10.1016/j.jneuroim.2010.01.013)

Received in final form 5 September 2012

Accepted 10 September 2012

Made available online as an Accepted Preprint

10 September 2012